This course has concluded on September 7, 2023

CE InformationCourse Outline

    Critical Limb Ischemia and Peripheral Artery Disease: Strategies to Optimize Patient Outcomes with Factor Xa Inhibitors

    FACULTY

    MODERATOR & SPEAKER
    Eric A. Secemsky, MD  
    Beth Israel Deaconess Medical Center and Harvard Medical School 
    Boston, Massachusetts

    SPEAKERS
    Nicolas Mouwad, MD 
    McLaren Bay Heart & Vascular
    Bay City, Michigan 

    Anahita Dua, MD 
    Massachusetts General Hospital / Harvard Medical School 
    Boston, Massachusetts 

    Ido Weinberg, MD
    Massachusetts General Hospital / Harvard Medical School 
    Boston, Massachusetts 

    PROVIDER STATEMENT

    Provided by HMP Education, an HMP Global Company.

    For questions regarding this educational activity, please call 609-371-1137 or email accreditation@hmpglobal.com.

    INTENDED LEARNERS

    This activity is designed for interventional cardiologists, vascular surgeons, interventional radiologists, wound care specialists, podiatrists, nurses, vascular technologists, and cardiovascular catheterization laboratory team members. 

    LEARNING OBJECTIVES

    After participating in this activity, learners should be better able to:

    • Assess the latest clinical data on factor Xa inhibitors and their optimal role in the management  
      of PAD 

    • Evaluate the role of factor Xa inhibitors in combination with aspirin to prevent adverse events  
      such as MALE 

    • Tailor appropriate management practices for treatment with factor Xa inhibitors based on  
      current guidelines, clinical recommendations, and patient-specific factors 

    CLAIMING CREDIT

    To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.

    Release Date: September 7, 2022 
    Expiration Date: September 7, 2023
    Estimated Time to Complete: 1 hour

    There is no fee associated with this activity.

    CONTINUING EDUCATION

    In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    PHYSICIANS

    HMP Education designates this internet live/enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    NURSES

    This continuing nursing education internet live/enduring activity awards 1 contact hour.

    Provider approved by the California Board of Registered Nursing, Provider #13255 for 1 contact hour. 

    NURSE PRACTITIONERS

    American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.

    PHYSICIAN ASSISTANTS

    HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet live/enduring activity is designated for 1 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.

    PODIATRISTS

    HMP Education is approved by the Council on Podiatric Medical Education as a provider of continuing education in podiatric medicine. HMP Education has approved this internet live/enduring activity for a maximum of 1 continuing education contact hour.

    VASCULAR & INTERVENTIONAL RADIOGRAPHERS

    Critical Limb Ischemia and Peripheral Artery Disease: Strategies to Optimize Patient Outcomes with Factor Xa Inhibitors taking place on demand has been approved for 1 A+ ARRT CE credits by the Association for Vascular and Interventional Radiographers (AVIR). The AVIR is an ARRT Recognized Continuing Education Evaluating Mechanism, (RCEEM).  Reference #AVIR220950R.


    USE OF PROPRIETARY NAMES

    This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

    UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

    This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of HMP Education.

    DISCLAIMERS

    The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

    Neither HMP Education nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

    The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Education or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

    DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

    HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

    In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real conflicts of interest between any individual with control over the content and any ineligible company (commercial interest) as defined by the ACCME.

    Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

    1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company, and;
    2. Any investigational, off-label, or non-FDA approved content or discussion

    HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

    Education has been independently peer-reviewed to validate content, mitigate identified conflicts of interest, and ensure:

    1. All recommendations involving clinical medicine is based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
    2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
    3. Content is appropriate, fair and balanced, unbiased, referenced, and non-promotional.

    FACULTY

    The faculty has reported the following:

    Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM – Abbott: Advisory Board, Consultant, Speaker's Bureau; Asahi, Bayer: Advisory Board, Consultant, Speaker's Bureau; BD: Advisory Board, Consultant, Speaker's Bureau; Boston Scientific: Advisory Board, Consultant, Speaker's Bureau; Cook: Advisory Board, Consultant, Speaker's Bureau; CSI: Advisory Board, Consultant, Speaker's Bureau; Inari: Advisory Board, Consultant, Speaker's Bureau; Janssen: Advisory Board, Consultant, Speaker's Bureau; Medtronic: Advisory Board, Consultant, Speaker's Bureau; Philips: Advisory Board, Consultant, Speaker's Bureau; VentureMed: Advisory Board, Consultant, Speaker's Bureau 

    Nicolas Mouawad, MD - Inari Medical: Speaker's Bureau; Janssen Pharmaceuticals: Speaker's Bureau 

    Anahita Dua, MD MS MBA FACS - Penumbra: Consultant, Contracted Research  

    Ido Weinberg, MD - Magneto Thrombectomy Solutions: Consultant; PENUMBRA INC: Consultant 
     

    CLINICAL REVIEWER

    Jihad Mustapha, MD
    Co-founder and CEO
    ACV Centers
    Grand Rapids, Michigan, United States

    Jihad A. Mustapha, MD, FACC, FSCAI - Angiodynamics: Consultant; Avinger: Consultant, Grant/Research Support; Becton Dickinson/CR Bard: Consultant; Boston Scientific: Consultant, Grant/Research Support; Cardio Flow: Grant/Research Support, Major Stockholder; Medtronic: Consultant; MicroMedical Solutions: Advisory Board; Philips Healthcare: Consultant; PQ Bypass: Advisory Board, Grant/Research Support; Reflow Medical: Advisory Board; TERUMO: Consultant  

    PLANNING COMMITTEE

    Susie Seaman, NP, MSN, CWCN, CWS (nurse planner)
    Wound Clinic, Family Health Centers of San Diego
    San Diego, California

    Ms. Seaman has disclosed no relevant financial relationship with any ineligible company (commercial interest).

    HMP Education planners and staff include Caitlin Eastman, MaryEllen Fama, Colleen Waters, Samantha Conforti, Randy Robbin, and Andrea Zimmerman.

    No HMP Education planner or staff has disclosed a relevant financial relationship with any ineligible company (commercial interest).

    ADA STATEMENT

    HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

    PRIVACY POLICY

    HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint providers. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

    Copyright © 2022 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.

    GRIEVANCE POLICY

    Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by HMP Education may contact Samantha Conforti, Senior Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@hmpglobal.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. Ms. Conforti will review the grievance and respond within 30 days of receiving the complaint.

    Commercial Support

    Supported by an independent educational grant from Janssen Scientific Affairs, LLC